

1 **Optimization of the Cultural parameters for**
2 **Improved Production of Antimicrobial**
3 **Metabolites by *Streptomyces gulbargensis* DAS**
4 **131^T**

5
6
7
8
9
10
11 **ABSTRACT**
12

Aims: To investigate the influence of appropriate culture medium by optimizing the cultural and environmental conditions affecting the growth and bioactive metabolite production by *Streptomyces gulbargensis* DAS 131^T under submerged culture conditions in order to reduce the cost of fermentation process and improve the formation of antimicrobial compounds.

Place and Duration of Study: Department of Botany and Microbiology, January 2012 to May 2012.

Methodology: The impact of environmental parameters such as incubation period, pH, temperature and salt concentration and effect of various nutrients such as carbon and nitrogen sources and minerals on the antimicrobial metabolite production by *Streptomyces gulbargensis* DAS 131^T was evaluated by employing agar well diffusion assay. Growth was measured in the form of dry mycelial weight.

Results: The optimum pH and temperature for bioactive metabolite production were 7 and 35°C respectively. Highest anti microbial metabolite production was found when the strain was inoculated into the medium amended with glucose @ 2%, soya peptone @ 1% and NaCl @ 5% and incubated for six days under shaking conditions. The metabolites showed good antimicrobial activity against Gram positive and Gram negative bacteria, as well as unicellular and multicellular fungi.

Conclusion: This is the first report on the optimization studies of bioactive metabolite production by *S.gulbargensis* DAS 131^T. It was found that the antimicrobial metabolite production by *S. gulbargensis* was positively influenced by carbohydrates, nitrogen sources and minerals. As the strain exhibited potent antimicrobial activity further studies regarding the characterization of bioactive compounds by *S. gulbargensis* are in progress.

13
14 **Keywords:** Optimization, Bioactive metabolites, Nutritional factors, Antimicrobial activity,
15 *Streptomyces gulbargensis* DAS 131^T.

16

17 1. INTRODUCTION

18

19 The microbes are the source for many important drugs including antibiotics, antitumor
20 compounds, Immunosuppressants, antiviral and antiparasitic agents. Over 10,000 of
21 bioactive compounds have been produced by Actinomycetes which contribute to 45% of all
22 the bioactive secondary metabolites discovered [1]. Microbes dwelling in extreme habitats
23 have been focused as an important source for novel compounds in recent years. The
24 majority of studies with microbes from extreme environments were confined to bacteria and
25 the actinomycetes from these habitats have been relatively less explored [2]. As highlighted
26 in many reviews [3], natural products are the origin for most of the antibiotics in the market
27 today. These products are an important source for both the existing and new drugs. Among
28 these, actinomycetes are a biotechnologically priceless group of prokaryotes. Actinobacteria
29 form a distinct line in the 16S rDNA tree and produce metabolites that have medical
30 contribution from antibiotics to enzyme inhibitors. They are ubiquitously distributed in
31 terrestrial, fresh water and extremophilic environments such as marine ecosystems and
32 alkali soils [4]. They are considered to be the important group of microbes due to their ability
33 to produce novel chemical compounds that are complex and commercially important (5). The
34 solution to combat multidrug resistance of pathogens is to search for novel antimicrobial
35 compounds so as to find a solution to overcome the global resistance to pathogenic bacteria.

36

37 It is widely accepted that alkaliphilic actinomycetes are a valuable source for medicinal and
38 industrial products [6]. Extensive exploration of actinomycetes having unique therapeutic
39 properties continues to be an important area of research. *Streptomyces* species belonging to
40 actinomycetes have been known as prolific producers of useful bioactive metabolites. These
41 species are also recognized as industrially important organisms for their ability to synthesize
42 different kinds of novel secondary metabolites, accounting for 70- 80% of all natural
43 compounds produced by actinomycetes. *Streptomyces* are well documented as source for
44 novel drug metabolites [7]. Some of the important compounds obtained from the alkaliphilic
45 *Streptomyces* species include Pyrocoll [8], Chinikomycin and Lajollamycin, Mediomyocins A
46 and B, Clethramycin [9], Bleomycin [10] and Caboxamycin [11] with anti-tumor, anti-parasitic
47 and anti-microbial properties. Several studies were aimed at isolation of *Streptomyces* and
48 screening them for new antibiotics. Novel actinomycetes documented and the products
49 derived from poorly explored habitats stress the need to probe into new habitats [2].

50

51 Media supplemented with carbon, nitrogen sources [12], sodium chloride [13] and mineral
52 salts [14] and physico-chemical parameters like temperature, pH and incubation period also
53 play a major role on growth and production of anti-microbial metabolites. The type, addition,
54 deletion and concentration of carbon, nitrogen, and phosphate together with trace elements
55 are reported to influence the antibiotic biosynthesis by *Streptomyces* [15]. In order to achieve
56 the highest level of metabolite production, the optimization of process parameters is very
57 critical [16, 17]. Hence an effort was made to understand the impact of different carbon and
58 nitrogen sources, temperature, pH and incubation period on growth and bioactive metabolite
59 production by *Streptomyces gulbargensis* DAS 131^T

60

61 2. MATERIALS AND METHODS

62

63 2.1. Isolation

64 During the course of screening for industrially important microorganisms, an alkali-tolerant
65 and thermo-tolerant actinomycete isolate identified as *Streptomyces gulbargensis* DAS 131^T
66 was isolated from semi-arid soils of Gulbarga, Northern Karnataka province, India, by
67 standard serial dilution technique using starch casein agar medium [18] and further

68 maintained on Yeast extract malt extract dextrose (ISP-2) agar medium at 4°C [19]. The
69 strain has been deposited in the NCBI genbank with the accession number DQ 317411 [20].
70

71 **2.2. Effect of Incubation period**

72 The growth pattern and bioactive metabolite production by the strain was studied at regular
73 intervals up to 10 days. One week old culture was cultivated in seed medium (ISP-2 broth) at
74 37°C for 48 h. Seed culture at a rate of 10% was inoculated into the production medium
75 (starch casein broth). The fermentation process was carried out for 10 days under agitation
76 at 150 rpm. At every 24 h interval, the flasks were harvested and the biomass was
77 separated from the culture filtrate. Biomass was determined in terms of dry weight and
78 antimicrobial metabolite production was determined in terms of their antimicrobial spectrum
79 [21]. The crude bioactive compound produced in the fermentation medium by the isolate was
80 extracted twice with equal volume of ethyl acetate (1:1) in a separating funnel at periodic
81 intervals. The solvent layer was collected and evaporated in a rotary evaporator under
82 vacuum. The crude residue thus obtained was dissolved in DMSO (Dimethylsulfoxide) at a
83 concentration of 1000µg/ml and employed for antimicrobial activity against test
84 microorganisms like *Streptococcus mutans* (MTCC 497), *Staphylococcus aureus* (MTCC
85 3160), *Salmonella typhi* (ATCC 14028), *Pseudomonas aeruginosa* (ATCC 9027) and
86 *Candida albicans* (ATCC 10231) by agar well diffusion method [22].
87

88 **2.3. Selection of culture conditions for the optimum production of bioactive 89 metabolites**

90 Antimicrobial metabolite production by the strain was optimized by using different
91 parameters such as pH, temperature, NaCl, carbon, nitrogen sources and minerals.
92

93 **2.4. Effect of pH and temperature**

94 To determine the influence of initial pH on growth and bioactive metabolite production, the
95 strain was cultivated in the medium with different initial pH values ranging from 5 to 10. The
96 strain was inoculated into production medium and grown at temperatures ranging from 20 to
97 50°C to study the impact of temperature. The biomass and bioactive metabolite production
98 were estimated and optimal pH and temperature achieved in this step was used for
99 subsequent study.

100

101 **2.5. Effect of NaCl concentration**

102 The impact of salinity on growth and bioactive metabolite production by *S. gulbargensis* DAS
103 131^T was recorded by cultivating the strain in the fermentation medium amended with
104 different concentrations of NaCl (1-10%).
105

106 **2.6. Effect of carbon and nitrogen sources**

107 To determine the effect of carbon sources on biomass and bioactive metabolite production,
108 different carbon sources like galactose, lactose, fructose, sucrose, glucose, starch, mannitol,
109 arabinose, raffinose and rhamnose each at a concentration of 1% were added separately
110 into the production medium. The effect of varying concentrations of the best carbon source
111 (0.5 - 5%) on bioactive metabolite production was examined. Similarly, the influence of
112 various nitrogen sources on antimicrobial metabolite production was evaluated by amending
113 different nitrogen sources like soya peptone, arginine, asparagine, meat extract, yeast
114 extract, tryptone, soya flour, casein, beef extract and glycine each at a concentration of 0.5%
115 were individually supplemented into the production medium containing an optimum amount
116 of the superior carbon source. Further, the impact of varying concentrations of optimized

117 nitrogen source (0.1-2%) was studied to standardize the maximum antimicrobial metabolite
 118 production.

119

120 **2.7. Impact of K₂HPO₄**

121 To study the impact of K₂HPO₄ on growth and bioactive metabolite production, the strain
 122 was grown in the fermentation medium amended with different concentrations of K₂HPO₄
 123 (0.01 to 0.1%).

124

125 **2.8. Statistical analysis**

126 Results on cell growth and the production of bioactive metabolites by *S. gulbargensis* under
 127 different cultural conditions tested are statistically analyzed with Two way analysis of
 128 variance (ANOVA).

129

130 The metabolites produced by the strain under optimized conditions were tested against
 131 bacteria and fungi by agar-well diffusion assay (22). The test microorganisms used to
 132 evaluate the production of bioactive metabolites were *Staphylococcus aureus* (MTCC 3160),
 133 *Streptococcus mutans* (MTCC 497), *Bacillus subtilis* (ATCC 6633), *Lactobacillus casei*
 134 (MTCC 1423), *Lactobacillus acidophilus* (MTCC 495), *Xanthomonas campestris* (MTCC
 135 2286), *Bacillus megaterium* (NCIM 2187), *Escherichia coli* (ATCC 35218), *Enterococcus*
 136 *faecalis* (MTCC 439), *Pseudomonas aeruginosa* (ATCC 9027), *Salmonella typhi* (ATCC
 137 14028), *Proteus vulgaris* (MTCC 7299), *Candida albicans* (ATCC 10231), *Aspergillus niger*,
 138 *Aspergillus flavus*, *Fusarium oxysporum* (MTCC 3075) and *Penicillium citrinum*.

139


140 **3. RESULTS AND DISCUSSION**

141

142 **3.1. Effect of incubation period**

143 The growth pattern of *S.gulbargensis* DAS 131^T was studied on starch casein broth. The
 144 stationary phase extended from 120 h to 144 h of incubation (Fig.1). The secondary
 145 metabolites obtained from six day old culture exhibited high antimicrobial activity against the
 146 test microorganisms which was in complete accordance with the earlier reports [23,7]. The
 147 incubation period for the production of bioactive metabolites seems to vary among
 148 *Streptomyces* strains. Metabolites elaborated from 5 day old culture of *Streptomyces* sp.
 149 KGG32 [24] and *S.ramulosus*-AZ-SH-29 [25] showed good anti microbial activity.
 150 Metabolites collected from 10-day old culture of Hygromycin-B producing *S.crystallinus* AZ-
 151 A151 exhibited good anti microbial activity [26].

152



153

154


155 Fig.1. Growth pattern and anti-microbial activity of *S. gulbargensis* DAS 131^T.

156 *Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and
 157 found to be significant at 1%.

158

159 **3.2. Effect of initial pH and incubation temperature**

160 The environmental requirements and cultural conditions for growth and bioactive metabolite
 161 production by *S. gulbargensis* DAS 131^T were studied. The antimicrobial metabolite
 162 production was found to be influenced by pH of the medium. The maximum biomass and
 163 bioactive metabolite production by the strain was obtained at pH 7 suggesting its inclusion in
 164 the neutrophilic actinomycetes group (Fig. 2). Medium maintained at pH 7.0 was reported to
 165 support enhanced anti microbial metabolite production by *Streptomyces rochei* G 164 [27],
 166 *Streptomyces marinensis* [28], *Streptomyces albidoflavus* [21], *Streptomyces torulosus* KH-4
 167 [29] and *Streptomyces cheonanensis* VUK-A [31].



168

169

170

171 Fig. 2. Effect of pH on growth and bioactive metabolite yield of *S. gulbargensis* DAS 131^T

172 *Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and
 173 found to be significant at 1%.


174

175 The increase of incubation temperature from 20°- 35°C enhanced the biomass and the
 176 production of bioactive metabolites (Fig.3). In terms of its optimum temperature for growth,
 177 the organism appeared to be mesophilic in nature. Atta *et al.* [26] reported that *Streptomyces*
 178 *crystallinus*, AZ-A151 produced high levels of Hygromycin-B production at 35°C.
 179 Ushakiranmayi *et al.* [33] stated that the optimum temperature capable of promoting
 180 antimicrobial metabolite produced by *Pseudonocardia* sp.VUK-10 isolated from
 181 Nizampatnam mangrove ecosystem was 35°C. Similar results have been reported earlier for
 182 several *Streptomyces* spp. [34, 21, 35, 30].

183

184

185



186
187
188
189
190

Fig.3. Effect of temperature on growth and bioactive metabolite yield of *S.gulbargensis* DAS 131^T.

191 *Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and
192 found to be significant at 1%.

193

194

3.3. Effect of NaCl

195

196

197

198

199

200

201


202

203

204

205

Optimum salt requirement for bioactive metabolite production was examined in the production medium supplemented with different salt concentrations ranging from 1-10%. NaCl @ 5% was found to be optimum for maximum growth as well as antimicrobial compound production by *S. gulbargensis* DAS 131^T (Fig. 4). Further increase in salt concentration reduced the antimicrobial agent biosynthesis. The requirement of NaCl for the production of bioactive metabolites seems to be different among actinomycete strains. Optimum NaCl concentration for maximum growth as well as antimicrobial metabolite production was reported to be 2% for *Streptomyces tanashiensis* A2D [2], 1% for *Streptomyces felleus* YJ1 [36] and 5% for *Streptomyces* VITSVK9 [30].



206
207
208

Fig. 4. Effect of NaCl on growth and bioactive metabolite yield of *S. gulbargensis* DAS 131^T.

209 *Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and
 210 found to be significant at 1%.


211

212 **3.4. Effect of carbon and nitrogen sources**

213 Carbon and nitrogen sources play key role as structural and energy compounds in cells to
 214 enhance antibiotic production. Information related to various carbon and nitrogen sources
 215 that support good microbial growth, maximize the product yield, minimize the synthesis of
 216 compounds closely related to the product and enhance product recovery is required [37, 38].

217

218 The effect of carbon sources on biomass and bioactive metabolite production by *S.*
 219 *gulbargensis* DAS 131^T was evaluated. The antimicrobial activity production seems to be no
 220 way correlated to the biomass yield (Fig. 5). The production of biomass was high with
 221 lactose followed by sucrose and starch, while significant bioactive metabolite production was
 222 obtained by the strain in glucose amended media followed by galactose and fructose. El-
 223 Enshasy *et al.* [39] reported that glucose and sucrose in pure or in polymer forms were the
 224 best C-sources for erythromycin production. Antibiotic production from alkaliphilic *S.*
 225 *tanashiensis* strain A2D was high in medium containing glucose as carbon source [2].
 226 Similarly glucose was found to be the best carbon source for antibiotic production by
 227 *Streptomyces torulosus* KH-4 [29], *S. griseocarneus* [40] and *S. kanamyceticus* M27 [41].
 228



229

230


231 Fig. 5. Effect of different carbon sources on growth and bioactive metabolite yield of *S.*

232 *gulbargensis* DAS 131^T.

233 *Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and
 234 found to be significant at 1%.

235


236 As glucose emerged as the most preferred carbon source for bioactive metabolite production
 237 by the strain, varying concentrations of glucose (0.5-5%) was tested to determine its optimal
 238 concentration. It is noted that glucose at 3% and 2% concentrations showed optimal yields of
 239 biomass and bioactive metabolites respectively (Fig.6). Medium containing 2% glucose
 240 supported maximum levels of Natamycin production by *Streptomyces natalensis* and
 241 *Thermomonospora* spp. [38, 42] while Atta *et al.* [25] reported that medium containing 2.5%
 242 glucose supported antibiotic production by *Streptomyces ramulosus* AZ-SH-29.
 243



244
245
246 Fig.6. Effect of different concentrations of glucose on growth and production of bioactive
247 metabolite by *S.gulbargensis* DAS 131^T.

248 *Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and
249 found to be significant at 1%.

250
251 Nitrogen sources are important for the production of bioactive metabolites by micro
252 organisms. Changes in the nature and concentration of nitrogen source seem to affect
253 antibiotic biosynthesis in different organisms. Different nitrogen sources were found to have
254 significant effect on growth and secondary metabolite production by *S. gulbargensis* DAS
255 131^T. Among the nitrogen sources tested amendment of soya peptone in the culture medium
256 enhanced the biomass and bioactive metabolite production by the strain (Fig. 7). Viana *et al.*
257 [43] recorded that soya bean flour increased the clavulanic acid production by *Streptomyces*
258 DAUFPE 3060. In contrast Thakur *et al.* [7] found that basal medium amended with
259 asparagine as nitrogen source was proved to be the best for 2-methylheptyl isonicotinate
260 production by *Streptomyces sp.*201.




261
262
263 Fig.7. Effect of different nitrogen sources on growth and bioactive metabolite production by
264 *S. gulbargensis* DAS 131^T.

265 *Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and
266 found to be significant at 1%.

267
268 Influence of different concentrations of soya peptone on the production of bioactive
269 metabolites is represented in Fig.8. It is noted that soya peptone at a concentration of 1.5%


270 and 1% exhibited optimal production of biomass and bioactive metabolites respectively.
 271 Himabindu and Jetty [44] reported that soya bean meal at a concentration of 1% and 0.5%
 272 enhanced growth and gentamicin production by *Micromonospora echinospora*. Whereas Qin
 273 Song *et al.* [36] stated that soya bean meal at a concentration of 2% increased the bioactive
 274 metabolite production by *Streptomyces felleus* YJ1.
 275



276
 277
 278 Fig.8. Effect of different concentrations of soya peptone on growth and production of
 279 bioactive metabolite by *S. gulbargensis* DAS 131[†].
 280 *Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and
 281 found to be significant at 1%.
 282

283 **3.5. Effect of K₂HPO₄**

284 Effect of K₂HPO₄ on biomass and bioactive metabolite production by the strain (Fig. 9) was
 285 studied. A slight enhancement in growth and antimicrobial activity was obtained in medium
 286 supplemented with 0.05% of K₂HPO₄. Ripa *et al.* [32] reported that among different minerals
 287 tested, K₂HPO₄ showed positive influence on antibiotic production by *Streptomyces* RUPA-
 288 08PR. Narayana and Vijayalakshmi [21] also recorded that K₂HPO₄ slightly enhanced the
 289 production of biomass and bioactive metabolites of *Streptomyces albidoflavus*. Production of
 290 gentamicin by *M.purpurea* and antibiotic tylosin by a *Streptomyces* sp. was inhibited by high
 291 phosphate concentrations [45, 46].
 292
 293



294
 295

296 Fig.9. Impact of K_2HPO_4 on growth and bioactive metabolite production of *S. gulbargensis*
 297 DAS 131^T.

298 *Data on cell growth and bioactive metabolite yield were statistically analyzed by Two-way ANOVA and
 299 found to be significant at 1%.


300
 301 The antimicrobial metabolite produced by the strain under optimized conditions was tested
 302 against various test bacteria and fungi (Table.1 & Fig.10). Among the bacteria tested,
 303 *Xanthomonas campestris* and *Bacillus megaterium* are highly sensitive to the metabolites
 304 produced by *S. gulbargensis* DAS 131^T followed by *Streptococcus mutans* and
 305 *Enterococcus faecalis*. Among the fungi tested, *Candida albicans* was highly sensitive to the
 306 metabolites produced by the strain followed by *Aspergillus niger* and *Aspergillus flavus*. A
 307 significant antimicrobial activity was reported on the opportunistic and pathogenic bacteria
 308 and fungi tested.

309
 310 Table1. Antimicrobial activity of *S.gulbargensis* against opportunistic and pathogenic
 311 bacteria and fungi under optimized conditions.
 312

Antimicrobial Activity of Bioactive Metabolite Produced by Strain - DAS-131 (<i>Streptomyces gulbargensis</i>) under Optimized Conditions	
Bacteria	
Test Microorganisms	Zone of Inhibition (mm)
<i>Staphylococcus aureus</i>	31
<i>Streptococcus mutans</i>	33
<i>Bacillus subtilis</i>	30
<i>Lactobacillus casei</i>	32
<i>Lactobacillus acidophilus</i>	31
<i>Xanthomonas campestris</i>	34
<i>Bacillus megaterium</i>	33
<i>E.coli</i>	31
<i>Enterococcus faecalis</i>	33
<i>Pseudomonas aeruginosa</i>	30
<i>Salmonella typhi</i>	27
<i>Proteus vulgaris</i>	28
Fungi	
<i>Candida albicans</i>	32
<i>Aspergillus niger</i>	27
<i>Aspergillus flavus</i>	26

<i>Fusarium oxysporum</i>	19
<i>Pencillium citrinum</i>	20

313
314



315
316

317 FIG. 10: Antimicrobial activity of *Streptomyces gulbargensis* DAS 131^T against A.
318 *Pseudomonas aeruginosa* B. *Escherichia coli* C. *Salmonella typhi* D. *Bacillus subtilis* E.
319 *Candida albicans*.

320
321

4. CONCLUSION

322 The results obtained in the present investigation revealed that the growth and bioactive
323 metabolite production of *S. gulbargensis* DAS 131^T is influenced by environmental and
324 cultural conditions. Metabolite production was high when the culture was grown in medium
325 containing glucose @ 20 g/L as carbon source, soya peptone @ 10 g/L as nitrogen source,
326 K₂HPO₄ @ 0.5g/L as mineral source and 5% NaCl with an initial pH 7 for six days at 35°C.
327

328 In the present study, the metabolites produced by *S. gulbargensis* DAS 131^T grown under
329 optimized conditions exhibited significant antimicrobial activity against Gram positive, Gram
330 negative bacteria and fungi. Hence, further studies regarding the purification,
331 characterization and identification of bioactive compounds produced by the strain are in
332 progress. This is the first report on the optimization of bioactive metabolites produced by
333 novel *S. gulbargensis* DAS 131^T.

334
335

ACKNOWLEDGEMENTS:

336 Financial assistance from CSIR, New Delhi is gratefully acknowledged.

337 **COMPETING INTERESTS**

338 Authors have declared that no competing interests exist.

339

340 **AUTHORS' CONTRIBUTIONS**

341 UKM performed the experimental part, MVL& DA designed the study and SP performed
342 literature search and statistical analysis. All authors read and approved the final manuscript.

343

344 **REFERENCES**

345

346 [1]. Bérdy J. Bioactive microbial metabolites. J Antibiot. 2005; 58 (1): 1–26.

347

348 [2]. Singh LS, Mazumdar S, Bora TC. Optimization of process parameters for growth and
349 bioactive metabolite production by a salt-tolerant and alkaliphilic actinomycete,
350 *Streptomyces tanashiensis* strain A2D. Journal de Mycologie Medicale. 2009;
351 19 (4): 225-223.

352

353 [3]. Blunt JW, Copp BR, Munro MHJ, Northcote PT, Prinsep MR. Marine natural products.
354 Natural Product Reports. 2010; 27 (2): 165-237.

355

356 [4]. Shuvankar B, Syed GD, Savita K. Biotechnological significance of Actinobacterial
357 research in India. Recent Research in Science and Technology.2012; 4(4): 31-
358 39.

359

360 [5]. Hopwood DA. Therapeutic treasures from the deep. Nature Chemical Biology.2007; 3
361 (8): 457-458.

362

363 [6]. Mitsuiki S, Sakai M, Moriyama Y, Goto M, Furukawa K. Purification and some
364 properties of keratinolytic enzyme from an alkaliphilic Nocardiosis spp. TOA-1.
365 Biosci Biotechnol Biochem. 2002; 66 (1):164-167.

366

367 [7]. Thakur D, Bora TC, Bordoloi GN, Mazumdar S. Influence of nutrition and culturing
368 conditions for optimum growth and antimicrobial metabolite production by
369 *Streptomyces spp.*201. Journal de Mycologie Medicale.2009; 19 (3): 161-167.

370

371 [8]. Dietera A, Hamm A, Fiedler HP, Goodfellow M, Muller WA, Brun RP. An antibiotic,
372 antiparasitic and antitumor compound produced by a novel alkaliphilic
373 *Streptomyces* strain. J Antibiot. 2003; 56 (7):639-646.

374

375 [9]. Cai P, Kong F, Fink P, Ruppen ME, Williamson RT, Keiko T. Polyene Antibiotics from
376 *Streptomyces mediocidicus*. J Nat Prod.2007; 70 (2):215-219.

377

378 [10]. Chen C, Si S, He Q, Xu H, Lu M, Xie Y. Isolation and characterization of antibiotic
379 NC0604, a new analogue of bleomycin. J Antibiot.2008; 61(12):747-751.

380

381 [11]. Hohmann C, Schneider K, Bruntner C, Irran E, Nicholson G, Bull AT. Caboxamycin, a
382 new antibiotic of the benzoxazole family produced by the deep-sea strain
383 *Streptomyces* sp, NTK 937. J Antibiot. 2009; 62 (2):99-104.

384

385 [12]. Adinarayana K, Prabhakar T, Srinivasulu V, Rao AM, Jhansi LP. Optimization of
386 process parameters for cephalosporin C production under solid state
387 fermentation from *Acremonium chrysogenum*. Process Biochem. 2001; 39 (2):
388 171-177.

389

390 [13]. Noaman NH, Fattah A, Khaleafa M, Zaky SH. Factors affecting antimicrobial activity of
391 *Synechococcus leopoliensis*. Microbiol Res. 2004; 159 (4): 395-402.

392

393 [14]. Basak K, Majumdar SK. Mineral nutrition of *Streptomyces kanamyceticus* for
394 Kanamycin formation. Antimicrob Agents Chemother. 1975; 8 (4):391-395.

395

396 [15]. Loun'es A, Lebrihi A, Benslimance C, Lefebvre G, Germain P. Regulation of spiramycin
397 synthesis in *Streptomyces ambofaciens*: effect of glucose and inorganic
398 phosphate. J Microbiol Biotechnol. 1996; 45 (1-2): 204-211.

399

400 [16]. Moita C, Feio SS, Nunes L, Joa M, Curto M. Optimization of physical factors on the
401 production of active metabolites by *Bacillus subtilis* 355 against wood surface
402 contaminant fungi. Int Biodeterior Biodegrad. 2005; 55 (4): 261-269.

403

404 [17]. Krishnakumar S, Premkumar J, Alexis Rajan R, Ravikumar S. Optimization of potential
405 antibiotic production by salt-tolerant actinomycetes *Streptomyces* sp.-MSU29
406 isolated from marine sponge. Int J Applied Bioengineering. 2011; 5(2): 12-17.

407

408 [18]. Kuster K, Williams ST. Selection of media for isolation of *Streptomyces*. Nature. 1964;
409 202(4935): 928-929.

410

411 [19].Williams ST, Cross T. Isolation, Purification, Cultivation and Preservation of
412 *Actinomycetes*. In Booth C, editor. Methods Microbiology. 4: 295-334, 1971.

413

414 [20]. Dastager GS, Wen A, Dayanand BS, Mudgulkar KT, Shu PT, Xin, Xiao YZ.
415 *Streptomyces gulbargensis* sp.nov., isolated from soil in Karnataka, India.
416 Antonie van Leeuwenhoek. 2007; 91 (2): 99-104.

417

418 [21]. Narayana KJP, Vijayalakshmi M. Optimization of antimicrobial metabolites production
419 by *Streptomyces albidoflavus*. Research journal of pharmacology 2008; 2 (1): 4-
420 7.

421

422 [22]. Cappuccino JG, Sherman N. Microbiology, Laboratory manual. Person education, INC,
423 New Delhi; 2004.

424

425 [23]. Yarbrough GG. Screening microbial metabolites for new drugs, theoretical and practical
426 issues. J Antibiot. 1993; 46 (4):535-544.

427

428 [24].Oskay M. Effects of some Environmental Conditions on Biomass and Antimicrobial
429 Metabolite Production by *Streptomyces* sp., KGG32. Int J Agric Biol. 2011;13
430 (3): 317-324.

431

- 432 [25].Atta HM, Bahobail AS, El-Sehrawi MH. Studies on Isolation, Classification and
433 Phylogenetic characterization of antifungal substance produced by
434 *Streptomyces albidoflavus*-143. New York Science Journal. 2011; 4 (3): 40-53.
435
- 436 [26].Atta HM, Afifi MM, Elshanawany AA, Abdoul-raouf AU, El-Adly AM. Production of
437 Hygromycin-B antibiotic from *Streptomyces crystallinus*., AZ-A151: II.
438 Parameters controlling of antibiotic production. Academia Arena. 2012; 4 (3):
439 37-52.
440
- 441 [27].Chattopadhyay D, Sen SK. Optimization of cultural conditions for antifungal antibiotic
442 accumulated by *Streptomyces rochei* G 164. Hindustan Antibiot Bull. 1997;39
443 (1): 64-71.
444
- 445 [28] Adinarayana K, Ellaiah P, Srinivasulu B, Bhavani R, Adinarayana G. Response surface
446 methodological approach to optimize the nutritional parameters for neomycin
447 production by *Streptomyces marinensis* under solid state fermentation. Process
448 Biochemistry. 2003; 38 (11):1565-1572.
449
- 450 [29].Atta HM, Bayoumi R, El-Sehrawi M, Aboshady A, Al-Humiany A. Biotechnological
451 application for producing some anti microbial agents by actinomycetes isolates
452 from Al-Khurmah Governorate. European Journal of Applied Sciences. 2010; 2
453 (3): 98-107.
454
- 455 [30]. Saurav K, Kannabiran K. Diversity and Optimization of process parameters for the
456 growth of *Streptomyces* VITSVK 9 sp. Isolation from Bay of Bengal, India.
457 Journal of Natural and Environment sciences 2010; 1(2): 56-65.
458
- 459 [31].Ushakiranmayi M, Sudhakar P, Krishna N, Vijayalakshmi M. Influence of cultural
460 conditions for improved production of bioactive metabolites by *Streptomyces*
461 *cheonanensis* VUK-A isolated from Coringa Mangrove Ecosystem. Current
462 Trends in Biotechnology and Pharmacy. 2012; 6 (1): 99-111.
463
- 464 [32].Ripa FA, Nikkon F, Zaman S, Khondkar P. Optimal conditions for antimicrobial
465 metabolites production from a new *Streptomyces* sp.Rupa-08 isolated from
466 Bangladesh Soil. Mycobiology. 2009; 37 (3): 211-214.
467
- 468 [33]. Mangamuri Usha Kiranmayi, Poda Sudhakar, Kamma Srinivasulu, Muvva
469 Vijayalakshmi. Optimization of culturing conditions for improved production of
470 bioactive metabolites by *Pseudonocardia* sp. VUK-10. Mycobiology. 2011; 39
471 (3): 174-181.
472
- 473 [34]. Kunnari T, Tuikkanen J, Hautala A, Hakala J, Ylihonko, K, Mantsala, P. Isolation and
474 characterization of 8- demethoxy steffimycins in *Streptomyces steffisburgensis*
475 by the nogalamycin biosynthesis genes. J Antibiot. 1997; 50 (6):496-501.
476
- 477 [35].Saha MR, Rifa FA, Islam MZ, Khondkar, P. Optimization of conditions and in vitro
478 antibacterial activity of secondary metabolite isolated from *Streptomyces* sp.
479 MNK 7. Journal of Applied Science Research. 2010; 6(5):453-459.
480

- 481 [36].Qin Song, Yun Huang, Hui Yang. Optimization of fermentation conditions for antibiotic
482 production by actinomycetes YJ1 strain against *Sclerotinia sclerotiorum*. J Agri
483 Sci. 2012; 4 (7): 95-102.
484
- 485 [37].Casida LE. Fermentation media, In: Casida, L.E. editor. Industrial Microbiology, John
486 Wiley and Sons, Inc, New York, USA; pp: 117-135.1987.
487
- 488 [38].Farid MA, El-Enshasy HA, Ei-Diwany AI, El-sayed EA. Optimization of the cultivation
489 medium for Natamycin production by *Streptomyces netalensis*. J Basic
490 Microbiol. 2000; 40 (3):157-166.
491
- 492 [39].El-Enshasy HA, Mohamed NA, Farid MA, El-Diwany AI. Improvement of erythromycin
493 production by *Saccharopolyspora erythrea* in molasses based medium through
494 cultivation medium optimization. Bioresour Technol. 2008; 99(10): 4263-4268.
495
- 496 [40].Cruz R, Arias ME, Solveri J. Nutritional requirements for the production of phyla
497 zoloisoquinolinone antibiotic by *Streptomyces griseocarneus* NCIMB 40447.
498 Appl Microbiol Biotechnol. 1999; 53(1):115-119.
499
- 500 [41].Pandey A, Shukla A, Majumdar SK. Utilization of carbon and nitrogen sources by
501 *Streptomyces kanamyceticus* M 27 for the production of an antibacterial
502 antibiotic. Afr J Biotechnol. 2005; 4(9): 909-910.
503
- 504 [42].Gupte M, Kulkarni, P. A study of anti-fungal antibiotic production by *Thermomonospora*
505 sp. MTCC 3340 using full factorial design. J Chem Tech Biotechnol. 2003;
506 78(6): 605-610.
507
- 508 [43]. Viana DA, Carneiro-Cunha MN, Araujo JM, Barros-Neto B, Lima-Filho JL, Converti A *et*
509 *al.* Screening of variables influencing the Clavulanic Acid Production by
510 *Streptomyces* DAUFPE 3060 strain. Appl Biochem Biotechnol. 2010; 160(6):
511 1797-1807.
512
- 513 [44].Himabindu M, Annapurna J. Optimization of nutritional requirements for gentamicin
514 production by *Micromonospora echinospora*. Indian J Experimental Biology.
515 2006; 44: 842-848.
516
517